The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX
Open accessAbstract
Purpose: To retrospectively evaluate the pattern of recurrence and outcome of node-negative breast cancer (BC) according to major subtypes. Patients and Methods: In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII and IX with centrally reviewed pathology data were included. BC subtypes were defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n = 369), and hormone receptor positive with high (luminal B–like [LB-like]; n = 763) or low (luminal A–like [LA-like]; n = 509) proliferative activity by Ki-67 labeling index. BC-free interval (BCFI) events were invasive BC recurrence in local, contralateral breast, nodal, bone, or visceral sites. Time to first site–specific recurrence was evaluated by using cumulative incidence and competing risks regression analysis. Results: Median follow-up was 12.5 years. The 10-year BCFI was higher for patients with LA-like (86%) BC compared with LB-like (76%), HER2 (73%), and TN (71%; P < .001) BC. TN and HER2 cohorts had higher hazard of BCFI event in the first 4 years after diagnosis (pre-trastuzumab). LB-like cohorts had a continuously higher hazard of BCFI event over time compared with LA-like cohorts. Ten-year overall survival was higher for LA-like (89%) compared with LB-like (83%), HER2 (77%), and TN (75%; P < .001) BC. LB-like subtypes had higher rates of bone as first recurrence site than other subtypes (P = .005). Visceral recurrence as first site was lower for the LA-like subgroup, with similar incidence among the other subgroups when treated with chemotherapy (P = .003). Conclusion: BC subtypes have different distant recurrence patterns over time. Defining different patterns of BC recurrence can improve BC care through surveillance guidelines and can guide the design of clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Use of Ranks in One-Criterion Variance Analysis
Kruskal, W. H., & Wallis, W. A. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483441 · Cited by 13,912
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationGoldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Self-citationSurvival analysis using the SAS system : a practical guide
Allison, P. D. (1995) · Medical Entomology and Zoology · Cited by 2,402
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Cited by
Colleoni, M., Sun, Z., Price, K. N., Karlsson, P., Forbes, J. F., Thürlimann, B., Gianni, L., Castiglione, M., Gelber, R. D., Coates, A. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3504 · Cited by 613
Self-citationMolecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Li, H., Zhu, Y., Burnside, E. S., Huang, E., Drukker, K., Hoadley, K. A., Fan, C., Conzen, S. D., Zuley, M., Net, J. M., et al. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.12 · Cited by 364
Follow-up strategies for women treated for early breast cancer
Moschetti, I., Cinquini, M., Lambertini, M., Levaggi, A., & Liberati, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001768.pub3 · Cited by 338
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment
Pinker, K., Chin, J., Melsaether, A. N., Morris, E. A., & Moy, L. (2018) · Radiology · doi:10.1148/radiol.2018172171 · Cited by 275
El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00346-1 · Cited by 268
Self-citationLiu, T., Huang, J., Liao, T., Pu, R., Liu, S., & Peng, Y. (2022) · IRBM · doi:10.1016/j.irbm.2020.12.002 · Cited by 137
Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth
McKee, A. M., Kirkup, B. M., Madgwick, M., Fowler, W. J., Price, C. A., Dreger, S. A., Ansorge, R., Makin, K. A., Caim, S., Le Gall, G., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103012 · Cited by 81
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer
Bak, M. J., Das Gupta, S., Wahler, J., & Suh, N. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.03.001 · Cited by 80
Metadata
- Authors
- Metzger-Filho, O., Sun, Z., Viale, G., Price, K. N., Crivellari, D., Snyder, R. D., Gelber, R. D., Castiglione-Gertsch, M., Coates, A. S., Goldhirsch, A., & Cardoso, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-09-01
- Volume
- 31
- Issue
- 25
- Pages
- 3083-3090
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103938232
- Cited by
- 343
- References
- 35
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.